Drug intelligence / Profile preview

vasopressin

Development stage: Approved
Lead developer: PH Health
Modality: Peptides
Administration: Intravenous, Intramuscular, Subcutaneous, Intranasal

Overview

Vasopressin is a peptide hormone used to increase blood pressure in patients with vasodilatory shock who are resistant to fluid and catecholamine therapy. It is also used to manage anti-diuretic hormone deficiency, such as in diabetes insipidus, by reducing urine flow through its action on renal V2 receptors. Additionally, vasopressin causes vasoconstriction via V1 receptors, which helps in increasing systemic vascular resistance and mean arterial blood pressure.

Brand names: VasostrictPitressin
Other names: antidiuretic hormone (ADH)arginine-vasopressin (AVP)

Targets

AVPR1B (Vasopressin V1b Receptor)AVPR2 (Arginine vasopressin V2 receptor)AVPR1A (Arginine vasopressin receptor 1A)Oxytocin receptor

Beyond the preview

Go deeper on vasopressin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vasopressin.

Explore the full profile